Isolation of circulating tumor cells from the blood of prostate cancer patients using an antibody-coated nanodetector: An explorative mono-center non-randomized blinded trial

GILUPI GmbH (Germany)0 个研究点目标入组 105 人开始时间: 2012年2月6日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Confirmed diagnosis of prostate cancer of any stage
•2. Written informed consent of the patient after explanation by the investigator
•1. Are patients which must have the diagnosis of any stages of Benign prostatic hyperplasia (BPH). But apart from this diagnosis, the patients are healthy.
•2. Written informed consent of the patient after explanation by the investigator
•1. Healthy female probands according to anamnestic and clinical criteria
•2. Written informed consent of the patient after explanation by the investigator

•For all groups
•1. Age > 18 years
•2. Known anaphylaxis
•3. Auto immunological diseases: Anti-phospholipid antibody syndrome (lupus anticoagulant), Goodpasture's syndrome, lupus erythematosus, relapsing polychondritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, antineutrophilic cytoplasmic antibody (ANCA); Immuno deficiencies: X-linked aggamaglobulinaemia (XLA), severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), selective IgA deficiency
•3. Known infection with: Hepatitis A, B and C, human immunodeficiency virus (HIV), herpes simplex virus (HSV), cytomegalovirus (CMV), syphilis, toxoplasmosis, tuberculosis
•4. Not allowed concomitant medication: oral anticoagulants (Phenprocoumon, Coumadin), Platelet aggregation inhibitors (clopidogrel, prasugrel, ASS); recurrent thrombosis and pulmonary embolism
•In addition for:
•Group A: heart rhythm disturbances, clinically significant hypotension or hypovolemia
•Group B:diagnosis prostate cancer
•Group C: pregnancy and lactation, malignant tumour

发起方

GILUPI GmbH (Germany)